Today: 30 June 2026
Browse Category

NYSE:NVO 10 February 2026 - 24 June 2026

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk (CPH:NOVO-B) gains as South Africa copycat order tops Ozempic, Wegovy local sales

Novo Nordisk’s B shares jumped 2.6% to 307.75 Danish crowns on Tuesday. The stock is up 5.1% since Friday’s close and has gained 9.9% over three sessions. The OMXC25 index in Copenhagen fell 0.07%. Novo put a new number out for investors: 84,500. That’s roughly how many compounded semaglutide units iDexis supplied each month in South Africa, the company told a court. Novo says that’s more than it sold of Ozempic and Wegovy combined in the country. A court order on Monday barred iDexis from compounding, supplying, and marketing the semaglutide products while they’re under regulatory review. Compounding in this case refers to pharmacies preparing or adjusting a drug for patients. The court filing doesn’t clarify if a unit from iDexis matches a Novo pack, so there’s no way to turn the number into revenue.
24 June 2026
····
Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause

Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause

Veru Inc. shares stayed active premarket Friday as the biotech said it has a supply deal with Novo Nordisk tied to a weight-loss study using Wegovy. Benzinga data had the stock at $3.70 before the open at 7:01 a.m. ET. The move followed Thursday’s rally, when it closed at $4.23, up 88% for the day. Veru is now trying to bring enobosarm, its oral selective androgen receptor modulator, into the packed obesity drug market. Investors are looking for new drugs that can work with GLP-1 medicines, not replace them. GLP-1 receptor agonists copy a gut hormone linked to appetite and blood sugar.
5 June 2026
···
Veru shares jump after Novo Nordisk deal draws traders

Veru shares jump after Novo Nordisk deal draws traders

Veru Inc. shares jumped over 100% Thursday. The small-cap biotech said it's got a clinical supply deal with Novo Nordisk for its obesity trial. That puts a major drugmaker next to one of the more speculative weight-loss names in the market. The stock traded up $2.53 to $4.78 in the afternoon, jumping 112% from its previous close. It earlier hit $7.04. Volume was near 69.4 million shares, well above typical levels for the company. Market cap was roughly $76.7 million at that price.
4 June 2026
··
Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Investors eye Hims & Hers Health Inc. as it approaches Monday’s first-quarter results, with attention locked on the future of its weight-loss segment—especially after the company pulled back from widely promoted compounded GLP-1 drugs. Earnings will post after the U.S. markets close, followed by a 5 p.m. ET conference call, according to Hims & Hers. That’s suddenly important, with forecasts tightening up. Wall Street’s consensus sits around $617 million for first-quarter revenue, and EPS is pegged between 3 and 4 cents, according to public estimate trackers. Hims shares finished Friday’s regular session at $28.46, ticking up to $29.07 in after-hours trading.
11 May 2026
····
Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk bumped up its 2026 forecast on Wednesday, buoyed by stronger-than-expected initial sales for its Wegovy weight-loss pill—a fresh win in its rivalry with Eli Lilly. In Copenhagen, the stock jumped up to 9.2% after Novo told investors it now expects this year’s drops in sales and profit to be less steep than it previously warned. This shift is significant for Novo, which has been working to regain investor trust after ceding space in the U.S. obesity market. Lilly has picked up share there with its injectable treatments and recently launched a pill of its own. GLP-1 drugs—these mimic a gut hormone involved in appetite regulation and blood sugar—have surged into one of pharma’s hottest growth segments.
6 May 2026
···
Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Prescriptions for Eli Lilly and Company’s new oral weight-loss drug Foundayo reached 3,707 in the U.S. during its second week, according to IQVIA data cited by analysts. That’s behind the early numbers seen for Novo Nordisk’s competing Wegovy pill and has weighed on Lilly shares. In its launch week, Foundayo saw 1,390 prescriptions. This figure is key: investors are watching the launch closely to gauge if Lilly can push past injectables like Zepbound and stay ahead in the obesity drug race. Pills may bring in patients who’d rather skip injections, though Novo already enjoys a head start—time on shelves, brand muscle, momentum.
24 April 2026
···
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk A/S’s Wegovy pill stayed ahead in the early going, with 18,410 U.S. prescriptions at the same stage of launch where Eli Lilly’s Foundayo managed 3,707 in its second week, according to analysts referencing IQVIA data. RBC Capital Markets analyst Trung Huynh flagged that it’s early days and comparisons can be tricky, but noted that Foundayo’s latest numbers are likely to be viewed as a disappointment. Investors are watching the numbers closely, looking for signs that weight-loss pills might expand the market beyond injections. That could mean more out-of-pocket customers and possibly change the dynamic between the two main players in the GLP-1 drug space. GLP-1 drugs work by acting on a hormone linked to appetite and blood sugar. Pills offer a needle-free alternative, but injections are still projected to account for a big share of the market.
24 April 2026
··
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health announced Thursday that its providers are now able to send prescriptions for Eli Lilly’s Zepbound vials, the Zepbound KwikPen, and the Foundayo pill directly to LillyDirect. With this move, the telehealth company is expanding its reach into branded obesity treatments. The company said that, combined with its previous Novo Nordisk partnership, it now offers what it describes as the full lineup of FDA-approved GLP-1 drugs on its platform. This shift is crucial for Hims, which is looking to step away from compounded versions—pharmacy-mixed imitations of branded drugs—right as U.S. regulators clamp down on the loopholes that allowed those products to proliferate during supply shortages. GLP-1s, a red-hot category of obesity and diabetes treatments known for curbing appetite and lowering blood sugar, now face a more competitive, cash-pay landscape. Lilly and Novo are slashing prices, doubling down on direct sales, and pushing harder into telehealth.
23 April 2026
···
Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health dropped 1.6% to $30.52 in afternoon trading Tuesday, sliding after Amazon rolled out a GLP-1 weight-management program via One Medical. Shares, which opened at $28.31 and touched a session low of $28.01, took a hit as the telehealth firm faces increased heat to revamp its weight-loss segment. Hims is making a significant pivot, stepping back from its more controversial compounded GLP-1 model—where pharmacies tailor-make drugs for individual patients—and instead moving toward branded, FDA-approved options. Back in March, the company announced it would stop marketing compounded GLP-1s, striking a deal with Novo Nordisk to add Ozempic and Wegovy to its platform.
21 April 2026
·····
Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket action as of 9:00 a.m. EDT on Thursday, following a 10.3% jump to $25.88 at Wednesday’s close. That put the telehealth company on track for its fourth consecutive advance. This surge traces back to a shift in Hims’ weight-loss strategy—not just a flash of momentum. The company locked in a new agreement with Novo Nordisk, settling their patent fight and putting FDA-approved Wegovy and Ozempic back in Hims’ lineup. As a result, Hims will largely drop compounded GLP-1 offerings, moving further from pharmacy-crafted alternatives in favor of the branded drugs that treat obesity and diabetes. Hims says Novo’s treatments hit the platform later this month.
12 March 2026
···
Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares surged 5.9% to finish at $23.47 on Tuesday, building on a two-day rally that’s now hit roughly 49%. The telehealth firm had closed at $15.74 back on March 6, then soared to $22.16 at Monday’s close. During Tuesday’s session, the stock swung from $22.43 up to $26.03 before easing back to settle below its session peak, following news of a fresh distribution deal with Novo Nordisk. This rebound is notable: Hims was squeezed by regulators and Novo, but now there’s relief. Novo pulled its lawsuit, at least for now—it can bring it back if needed—removing a big cloud hanging over the company. The deal pushes Hims away from compounded GLP-1s—those pharmacy-mixed obesity treatments—and onto branded, FDA-approved drugs instead.
11 March 2026
··
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

NORTH CHICAGO, Illinois, March 10, 2026, 14:19 CDT. AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.
10 March 2026
····
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

New York, Feb 26, 2026, 08:43 EST — Premarket Hims & Hers Health shares nudged 0.3% higher ahead of Thursday’s open, building on Wednesday’s 2.3% advance. The telehealth firm wrapped up the last session at $15.82, after trading in a range from $15.06 to $16.46 during the day. On Tuesday, the stock had dropped to $13.74.
26 February 2026
···
1 2 3 … 7

Stock Market Today

  • Electro Optic Systems (ASX:EOS) jumps 5.6% on S&P/ASX 200 move, outlook mixed
    June 30, 2026, 6:57 AM EDT. Shares in Electro Optic Systems Holdings (ASX: EOS) rose 5.6% after the stock was added to both the S&P/ASX 200 and Industrials Sector indices, raising its profile and boosting liquidity. The news could pull in flows from index funds and more institutional money. EOS makes counter drone, laser, and space control tech, aiming to turn defense deals into steady revenue. A recent €10 million investment in a European AI-based drone defense hub fits this plan. Still, the company faces recurring risks around its heavy dependence on big defense contracts and swings in financials. Market forecasts point to A$514.7 million revenue and A$62.6 million earnings by 2029, with some analysts seeing about 26% upside to fair value near A$12.94. But analyst views are split, and the outlook remains unsettled as the story develops.
Go toTop